Exscientia
Uses AI to design patient first precision medicines and optimize clinical trials.
What they do
Exscientia operates an artificial intelligence platform to design small molecule drugs and match patients with optimal treatments. The platform automates drug design and evaluates drug efficacy on actual human tissue samples to assist biopharmaceutical partners.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Oxford, United Kingdom
- Region
- Europe
- Founded
- 2012
- Total funding
- $440M raised
Notable investors: SoftBank Vision Fund, Mubadala Investment Company, BlackRock, Bristol Myers Squibb.